GRI Bio (GRI), a biotechnology company, on Tuesday reported interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for Idiopathic Pulmonary Fibrosis or IPF.
The study demonstrated that GRI-0621 (4.5mg, taken orally once daily) was safe and well-tolerated in the first 12 patients evaluated. No significant changes were observed in LDL, HDL, triglyceride, or total cholesterol (TG) levels, as assessed at the 2-week visit.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.